Industry Primer — Healthcare
Drug discovery and biotechnology companies develop novel therapeutics using biological systems, genetic engineering, and advanced chemistry. The global biotech market exceeds $600 billion in revenue, with the U.S. representing roughly half. The sector spans large-cap commercial-stage companies (Vertex, Regeneron, Gilead) through thousands of clinical and pre-clinical stage companies funded by venture capital and public markets. Biotech is characterized by high risk/high reward economics — the average drug takes 10-15 years and $2-3 billion to develop, with roughly 10% probability of clinical success.
The sector is emerging from a difficult biotech funding cycle. IPO activity and secondary offerings are recovering from 2022-2023 lows. GLP-1/obesity represents the largest therapeutic wave in decades, with massive investment across the value chain. Oncology remains the largest therapeutic area by R&D spend. Cell and gene therapy approvals are accelerating, though manufacturing and pricing challenges persist. Large pharma M&A is robust as patent cliffs drive pipeline acquisition needs — Pfizer, AbbVie, Merck, and Bristol-Myers have all been active acquirers.
Over five years, several transformative therapeutic modalities will mature. RNA therapeutics (mRNA, siRNA, ASO) will expand beyond rare diseases into large chronic condition markets. Cell therapy manufacturing will be industrialized, reducing costs from $400K+ per treatment. Gene editing (CRISPR) will move from rare disease to broader applications. AI-designed drugs will enter late-stage clinical trials, validating computational drug discovery. Antibody-drug conjugates (ADCs) and bispecific antibodies will become standard oncology treatments.
The long-term vision is programmable medicine — the ability to precisely intervene in any biological pathway with engineered molecules, cells, or genetic modifications. Curative gene therapies for hundreds of genetic diseases will reshape healthcare economics. Synthetic biology will enable manufacturing of complex biological therapeutics at commodity scale. AI will compress discovery-to-approval timelines from 15 years to 5-7 years. The key challenge is pricing and reimbursement — curative therapies command high prices that healthcare systems struggle to absorb.
Clinical trial success rates (probability of technical success) determine company value. FDA regulatory timelines and approval decisions create binary outcomes. Patent protection and exclusivity periods define revenue duration. Pricing and payer coverage decisions determine commercial potential. Biotech venture capital and IPO market conditions influence funding availability. Manufacturing complexity and cost for biologics impact margins. Large pharma partnership and acquisition activity provides liquidity for development-stage companies.
AI is fundamentally changing drug discovery. AlphaFold and similar tools predict protein structures with atomic accuracy, enabling rational drug design. Generative AI designs novel molecules with desired properties, reducing lead identification from years to months. Machine learning predicts ADMET properties (absorption, distribution, metabolism, excretion, toxicity) early in development, reducing late-stage attrition. AI optimizes clinical trial design — patient selection, dosing, endpoints — improving probability of success. Real-world evidence analytics accelerate post-approval label expansions.
Biotech firms can leverage AI-powered computational chemistry and molecular modeling to accelerate lead compound identification, potentially reducing early-stage discovery timelines by 30-50%. Machine learning models trained on clinical trial data improve patient selection and protocol design, reducing trial failure rates. Automated lab processes and electronic lab notebooks improve reproducibility and reduce manual error. Real-world evidence analytics support regulatory submissions and post-market studies.
Vertex Pharmaceuticals (VRTX) dominates cystic fibrosis treatment and is expanding into pain and gene editing. Regeneron (REGN) develops monoclonal antibodies across multiple therapeutic areas. Gilead Sciences (GILD) leads in HIV and hepatology. Alnylam Pharmaceuticals (ALNY) pioneers RNA interference therapeutics. BioMarin (BMRN) specializes in enzyme replacement therapies for rare diseases. Sarepta Therapeutics (SRPT) focuses on genetic medicine for neuromuscular diseases.